Eli Lilly partners with Amplitude Therapeutics to develop taRNA vaccines
Eli Lilly (LLY) has entered into a collaboration agreement with privately held biotech firm Amplitude Therapeutics to co-develop trans-amplifying RNA (taRNA) vaccine candidates for infectious diseases. The partnership aims to focus on programs addressing high unmet medical needs, though financial terms of the deal were not disclosed. This move aligns with Eli Lilly's broader strategy in expanding its portfolio into innovative therapeutic modalities such as mRNA-based vaccines. Amplitude Therapeutics specializes in taRNA technology, which has shown potential for enhanced immune responses and reduced dosing requirements compared to traditional RNA platforms. The collaboration could position both companies at the forefront of next-generation vaccine development. The partnership is expected to drive research innovation but may not immediately impact Eli Lilly's financials due to the early-stage nature of the programs.
Tickers: $LLY
Topics: Pharmaceuticals RNA Technology Vaccines